ERBB2 and anemia: The spectrum and incidence of AEs were similar to those observed with KN026 or KN046 monotherapy and other HER2 ECD2/4 antibodies or immunotherapies.23–26,37,38 Anemia was the most common form of hematological toxicity, with an incidence of 37.2%.